Effect and mechanism of transient receptor potential canonical channel 3 on hyperoxic lung injury in neonatal rats

Abstract

The aim of this study is to research the expression of the transient receptor potential canonical channel 3 (TRPC3) in a neonatal hyperoxic lung injury model of bronchopulmonary dysplasia (BPD), and to further investigate the role of the TRPC3/nuclear factor-κB (NF-κB) signaling pathway in hyperoxia-induced BPD by a TRPC3 agonist (GSK1702934A). The hyperoxic lung injury model of BPD was established in Sprague–Dawley neonatal rats. Hematoxylin and eosin (HE) staining and radial alveolar count (RAC) values showed that the hyperoxic lung injury model of BPD was successfully established in the neonatal rats, and pulmonary edema was found in the neonatal rats with BPD. The results of reference transcriptome sequencing, Quantitative real-time PCR (qPCR), and western blot showed lower pulmonary expression of TRPC3 in the BPD group than in the control group. Immunofluorescence showed predominant expression of TRPC3 in airways and pulmonary vessels, and the fluorescence intensity of the BPD group was lower than that of the control group. Lung dry-to-wet weight ratio, HE staining, and RAC value showed that the lung histomorphology significantly improved in the BPD + TRPC3 agonist group compared with the BPD group on day 14 but did not revert to the level of the control group. According to qPCR results, compared with the control group, the expression of NF-κB1 decreased and the expression of NF-κBiz increased in the BPD group, whereas the expression of NF-κBiz decreased in the BPD + TRPC3 agonist group. Therefore, we draw the conclusion that TRPC3 may activate NF-κB by inhibiting NF-κBiz to promote cell proliferation and lung growth and development.

Keywords

bronchopulmonary dysplasia / calcium ion channels / TRPC3 / TRPC3 agonists

References

[1] Thébaud B, Goss KN, Laughon M, et al. Bronchopulmonary dysplasia. Nat Rev Dis Prim. 2019;5(1):78.

[2] Lui K, Lee SK, Kusuda S, et al. Trends in outcomes for neonates born very preterm and very low birth weight in 11 high-income countries. J Pediatr. 2019;215:32-40.e14.

[3] Bonadies L, Zaramella P, Porzionato A, Perilongo G, Muraca M, Baraldi E. Present and future of bronchopulmonary dysplasia. J Clin Med. 2020;9(5):1539.

[4] Philip AG. Chronic lung disease of prematurity: a short history. Seminars Fetal & Neonatal Med. 2009;14(6):333-338.

[5] You JY, Shu C, Gong CH, Liu S, Fu Z. Readmission of children with bronchopulmonary dysplasia in the first 2 years of life: a clinical analysis of 121 cases. Chin J Contemp Pediatr. 2017;19(10):1056-1060.（in Chinese revision）

[6] Kalikkot Thekkeveedu R, Guaman MC, Shivanna B. Bronchopulmonary dysplasia: a review of pathogenesis and pathophysiology. Respir Med. 2017;132:170-177.

[7] Hwang JS, Rehan VK. Recent advances in bronchopulmonary dysplasia: pathophysiology, prevention, and treatment. Lung. 2018;196(2):129-138.

[8] Clapham DE. Calcium signaling. Cell. 2007;131(6):1047-1058.

[9] Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. Physiol Rev. 2006;86(1):279-367.

[10] Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S20-S31.

[11] Moran MM. TRP channels as potential drug targets. Annu Rev Pharmacol Toxicol. 2018;58:309-330.

[12] Gao YY, Tian W, Zhang HN, et al. Canonical transient receptor potential channels and their modulators: biology, pharmacology and therapeutic potentials. Arch Pharm Res. 2021;44(4):354-377.

[13] Golovina VA, Platoshyn O, Bailey CL, et al. Upregulated TRP and enhanced capacitative Ca(2+) entry in human pulmonary artery myocytes during proliferation. Am J Physiol Heart Circ Physiol. 2001;280(2):H746-H755.

[14] Yu Y, Fantozzi I, Remillard CV, et al. Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci U S A. 2004;101(38):13861-13866.

[15] Song T, Hao Q, Zheng YM, Liu QH, Wang YX. Inositol 1,4,5-trisphosphate activates TRPC3 channels to cause extracellular Ca2+ influx in airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2015;309(12):L1455-L1466.

[16] Zergane M, Kuebler WM, Michalick L. Heteromeric TRP channels in lung inflammation. Cells. 2021;10(7):1654.

[17] Chen X, Sooch G, Demaree IS, White FA, Obukhov AG. Transient receptor potential canonical (TRPC) channels: then and now. Cells. 2020;9(9):1983.

[18] Spassova MA, Hewavitharana T, Xu W, Soboloff J, Gill DL. A common mechanism underlies stretch activation and receptor activation of TRPC6 channels. Proc Natl Acad Sci U S A. 2006;103(44):16586-16591.

[19] Groschner K, Rosker C, Lukas M. Role of TRP channels in oxidative stress. Novartis Found Symp. 2004;258:222-230.

[20] Wang L, Li J, Zhang J, et al. Inhibition of TRPC3 downregulates airway hyperresponsiveness, remodeling of OVA-sensitized mouse. Biochem Biophys Res Commun. 2017;484(1):209-217.

[21] Masson B, Saint-Martin Willer A, Dutheil M, et al. Contribution of transient receptor potential canonical channels in human and experimental pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2023;325(2):L246-L261.

[22] Shin S, Gombedza FC, Awuah Boadi E, Yiu AJ, Roy SK, Bandyopadhyay BC. Reduction of TRPC1/TRPC3 mediated Ca(2+)-signaling protects oxidative stress-induced COPD. Cell Signal. 2023;107:110681.

[23] Zuo J, Tong Y, Yang Y, Wang Y, Yue D. Claudin-18 expression under hyperoxia in neonatal lungs of bronchopulmonary dysplasia model rats. Front Pediatr. 2022;10:916716.

[24] Wang Y, Liu L, Tao H, Wen L, Qin S. TRPC6 participates in the development of blood pressure variability increase in sino-aortic denervated rats. Heart Vessels. 2020;35(12):1755-1765.

[25] O'Reilly M, Thébaud B. Animal models of bronchopulmonary dysplasia. The term rat models. Am J Physiol Lung Cell Mol Physiol. 2014;307(12):L948-L958.

[26] Mcdaniel SS, Platoshyn O, Wang J, et al. Capacitative Ca(2+) entry in agonist-induced pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol. 2001;280(5):L870-L880.

[27] Alvira CM. Nuclear factor-kappa-B signaling in lung development and disease: one pathway, numerous functions. Birth Defects Res A Clin Mol Teratol. 2014;100(3):202-216.

[28] Napetschnig J, Wu H. Molecular basis of NF-κB signaling. Annu Rev Biophys. 2013;42:443-468.

[29] Iosef C, Alastalo TP, Hou Y, et al. Inhibiting NF-κB in the developing lung disrupts angiogenesis and alveolarization. Am J Physiol Lung Cell Mol Physiol. 2012;302(10):L1023-L1036.

[30] Hayden MS, Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012;26(3):203-234.

[31] Willems M, Dubois N, Musumeci L, Bours V, Robe PA. IκBζ: an emerging player in cancer. Oncotarget. 2016;7(40):66310-66322.

[32] Alvira CM, Abate A, Yang G, Dennery PA, Rabinovitch M. Nuclear factor-kappaB activation in neonatal mouse lung protects against lipopolysaccharide-induced inflammation. Am J Respir Crit Care Med. 2007;175(8):805-815.

[33] Mckenna S, Michaelis KA, Agboke F, et al. Sustained hyperoxia-induced NF-κB activation improves survival and preserves lung development in neonatal mice. Am J Physiol Lung Cell Mol Physiol. 2014;306(12):L1078-L1089.

[34] Dolmetsch RE, Xu K, Lewis RS. Calcium oscillations increase the efficiency and specificity of gene expression. Nature. 1998;392(6679):933-936.

[35] Bair AM, Thippegowda PB, Freichel M, et al. Ca2+ entry via TRPC channels is necessary for thrombin-induced NF-kappaB activation in endothelial cells through AMP-activated protein kinase and protein kinase Cdelta. J Biol Chem. 2009;284(1):563-574.

[36] Casas J, Meana C, López-López JR, Balsinde J, Balboa MA. Lipin-1-derived diacylglycerol activates intracellular TRPC3 which is critical for inflammatory signaling. Cell Mol Life Sci. 2021;78(24):8243-8260.

[37] Chung KW, Jeong HO, Lee B, et al. Involvement of NF-κBIZ and related cytokines in age-associated renal fibrosis. Oncotarget. 2017;8(5):7315-7327.

[38] Wang YX, Wang L, Zheng YM. Canonical transient potential receptor-3 channels in normal and diseased airway smooth muscle cells. Adv Exp Med Biol. 2020;1131:471-487.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Pediatric Discovery published by John Wiley & Sons Australia, Ltd on behalf of Children's Hospital of Chongqing Medical University.